vs
布鲁克（BRKR）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是HARVARD BIOSCIENCE INC的41.2倍（$977.2M vs $23.7M）。布鲁克净利率更高（2.7% vs -12.0%，领先14.7%）。布鲁克同比增速更快（-0.2% vs -3.3%）。布鲁克自由现金流更多（$207.2M vs $-545.0K）。过去两年布鲁克的营收复合增速更高（16.4% vs -1.6%）
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
BRKR vs HBIO — 直观对比
营收规模更大
BRKR
是对方的41.2倍
$23.7M
营收增速更快
BRKR
高出3.1%
-3.3%
净利率更高
BRKR
高出14.7%
-12.0%
自由现金流更多
BRKR
多$207.7M
$-545.0K
两年增速更快
BRKR
近两年复合增速
-1.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $977.2M | $23.7M |
| 净利润 | $26.0M | $-2.8M |
| 毛利率 | 46.0% | 59.7% |
| 营业利润率 | 7.8% | 7.2% |
| 净利率 | 2.7% | -12.0% |
| 营收同比 | -0.2% | -3.3% |
| 净利润同比 | 89.8% | -15916.7% |
| 每股收益（稀释后） | $0.10 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRKRHBIO
| Q4 25 | $977.2M | $23.7M | ||
| Q3 25 | $860.5M | $20.6M | ||
| Q2 25 | $797.4M | $20.4M | ||
| Q1 25 | $801.4M | $21.8M | ||
| Q4 24 | $979.6M | $24.6M | ||
| Q3 24 | $864.4M | $22.0M | ||
| Q2 24 | $800.7M | $23.1M | ||
| Q1 24 | $721.7M | $24.5M |
净利润BRKRHBIO
| Q4 25 | $26.0M | $-2.8M | ||
| Q3 25 | $-59.6M | $-1.2M | ||
| Q2 25 | $7.6M | $-2.3M | ||
| Q1 25 | $17.4M | $-50.3M | ||
| Q4 24 | $13.7M | $18.0K | ||
| Q3 24 | $40.9M | $-4.8M | ||
| Q2 24 | $7.6M | $-2.9M | ||
| Q1 24 | $50.9M | $-4.7M |
毛利率BRKRHBIO
| Q4 25 | 46.0% | 59.7% | ||
| Q3 25 | 44.1% | 58.4% | ||
| Q2 25 | 44.9% | 56.4% | ||
| Q1 25 | 48.8% | 56.0% | ||
| Q4 24 | 50.4% | 57.1% | ||
| Q3 24 | 48.4% | 58.1% | ||
| Q2 24 | 48.0% | 57.2% | ||
| Q1 24 | 48.9% | 60.3% |
营业利润率BRKRHBIO
| Q4 25 | 7.8% | 7.2% | ||
| Q3 25 | -6.0% | 1.0% | ||
| Q2 25 | 1.5% | -4.0% | ||
| Q1 25 | 4.0% | -228.1% | ||
| Q4 24 | 7.4% | 0.0% | ||
| Q3 24 | 7.9% | -8.5% | ||
| Q2 24 | 6.0% | -9.0% | ||
| Q1 24 | 9.0% | -9.3% |
净利率BRKRHBIO
| Q4 25 | 2.7% | -12.0% | ||
| Q3 25 | -6.9% | -6.0% | ||
| Q2 25 | 1.0% | -11.2% | ||
| Q1 25 | 2.2% | -231.2% | ||
| Q4 24 | 1.4% | 0.1% | ||
| Q3 24 | 4.7% | -21.9% | ||
| Q2 24 | 0.9% | -12.7% | ||
| Q1 24 | 7.1% | -19.1% |
每股收益（稀释后）BRKRHBIO
| Q4 25 | $0.10 | $-0.06 | ||
| Q3 25 | $-0.41 | $-0.03 | ||
| Q2 25 | $0.05 | $-0.05 | ||
| Q1 25 | $0.11 | $-1.14 | ||
| Q4 24 | $0.09 | $0.01 | ||
| Q3 24 | $0.27 | $-0.11 | ||
| Q2 24 | $0.05 | $-0.07 | ||
| Q1 24 | $0.35 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $298.8M | $8.6M |
| 总债务越低越好 | $1.9B | $35.9M |
| 股东权益账面价值 | $2.5B | $13.7M |
| 总资产 | $6.2B | $80.1M |
| 负债/权益比越低杠杆越低 | 0.76× | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资BRKRHBIO
| Q4 25 | $298.8M | $8.6M | ||
| Q3 25 | $293.1M | $6.8M | ||
| Q2 25 | $92.0M | $7.4M | ||
| Q1 25 | $184.2M | $5.5M | ||
| Q4 24 | $183.4M | $4.1M | ||
| Q3 24 | $148.1M | $4.6M | ||
| Q2 24 | $169.7M | $4.0M | ||
| Q1 24 | $340.1M | $4.3M |
总债务BRKRHBIO
| Q4 25 | $1.9B | $35.9M | ||
| Q3 25 | $2.0B | $34.0M | ||
| Q2 25 | $2.4B | $34.9M | ||
| Q1 25 | $2.1B | $36.4M | ||
| Q4 24 | $2.1B | $37.0M | ||
| Q3 24 | $2.3B | $34.9M | ||
| Q2 24 | $2.2B | $35.7M | ||
| Q1 24 | $1.4B | $35.6M |
股东权益BRKRHBIO
| Q4 25 | $2.5B | $13.7M | ||
| Q3 25 | $2.4B | $14.1M | ||
| Q2 25 | $1.8B | $15.7M | ||
| Q1 25 | $1.8B | $14.8M | ||
| Q4 24 | $1.8B | $63.3M | ||
| Q3 24 | $1.8B | $65.3M | ||
| Q2 24 | $1.8B | $67.2M | ||
| Q1 24 | $1.4B | $68.8M |
总资产BRKRHBIO
| Q4 25 | $6.2B | $80.1M | ||
| Q3 25 | $6.4B | $78.0M | ||
| Q2 25 | $6.3B | $80.1M | ||
| Q1 25 | $5.9B | $79.8M | ||
| Q4 24 | $5.8B | $126.6M | ||
| Q3 24 | $6.1B | $131.2M | ||
| Q2 24 | $5.9B | $128.9M | ||
| Q1 24 | $4.5B | $133.2M |
负债/权益比BRKRHBIO
| Q4 25 | 0.76× | 2.61× | ||
| Q3 25 | 0.83× | 2.41× | ||
| Q2 25 | 1.34× | 2.22× | ||
| Q1 25 | 1.15× | 2.45× | ||
| Q4 24 | 1.18× | 0.58× | ||
| Q3 24 | 1.27× | 0.53× | ||
| Q2 24 | 1.21× | 0.53× | ||
| Q1 24 | 0.97× | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.8M | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | $207.2M | $-545.0K |
| 自由现金流率自由现金流/营收 | 21.2% | -2.3% |
| 资本支出强度资本支出/营收 | 2.3% | 1.9% |
| 现金转化率经营现金流/净利润 | 8.84× | — |
| 过去12个月自由现金流最近4个季度 | $43.3M | $5.5M |
8季度趋势，按日历期对齐
经营现金流BRKRHBIO
| Q4 25 | $229.8M | $-96.0K | ||
| Q3 25 | $-33.2M | $1.1M | ||
| Q2 25 | $-127.5M | $2.8M | ||
| Q1 25 | $65.0M | $3.0M | ||
| Q4 24 | $190.0M | $1.7M | ||
| Q3 24 | $38.4M | $-842.0K | ||
| Q2 24 | $1.1M | $-846.0K | ||
| Q1 24 | $21.8M | $1.4M |
自由现金流BRKRHBIO
| Q4 25 | $207.2M | $-545.0K | ||
| Q3 25 | $-54.1M | $877.0K | ||
| Q2 25 | $-148.8M | $2.7M | ||
| Q1 25 | $39.0M | $2.5M | ||
| Q4 24 | $153.3M | $1.4M | ||
| Q3 24 | $5.8M | $-1.7M | ||
| Q2 24 | $-23.5M | $-1.7M | ||
| Q1 24 | $400.0K | $758.0K |
自由现金流率BRKRHBIO
| Q4 25 | 21.2% | -2.3% | ||
| Q3 25 | -6.3% | 4.3% | ||
| Q2 25 | -18.7% | 13.0% | ||
| Q1 25 | 4.9% | 11.4% | ||
| Q4 24 | 15.6% | 5.8% | ||
| Q3 24 | 0.7% | -7.8% | ||
| Q2 24 | -2.9% | -7.2% | ||
| Q1 24 | 0.1% | 3.1% |
资本支出强度BRKRHBIO
| Q4 25 | 2.3% | 1.9% | ||
| Q3 25 | 2.4% | 1.0% | ||
| Q2 25 | 2.7% | 0.4% | ||
| Q1 25 | 3.2% | 2.4% | ||
| Q4 24 | 3.7% | 1.2% | ||
| Q3 24 | 3.8% | 4.0% | ||
| Q2 24 | 3.1% | 3.5% | ||
| Q1 24 | 3.0% | 2.6% |
现金转化率BRKRHBIO
| Q4 25 | 8.84× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.78× | — | ||
| Q1 25 | 3.74× | — | ||
| Q4 24 | 13.87× | 95.83× | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
